[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lactose-intolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lactose-intolerance":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,73,103,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100555510","milk-for-diabetes-prevention-100555510",false,"NCT06513026","Milk for Diabetes Prevention","Inclusion Criteria:\n\n* LNP genotype (LCT gene rs4988235, GG genotype)\n* History of pre-diabetes, defined as fasting blood glucose 100-125 mg\u002FdL and\u002For hemoglobin A1c (HbA1c) 5.7-6.4% and have not been diagnosed with diabetes nor take diabetes medication (pre-diabetes determined at most recent study visit \\[for HCHS\u002FSOL participant\\] or most recent medical chart or self-report \\[for other participant\\])\n* Drink ≤1 cup milk\u002Fday\n* Basic computer or smartphone skills\n* Can speak and read English fluently\n\nExclusion Criteria:\n\n* Diabetes diagnosis\n* Taking anti-diabetes medication\n* Cancer, cardiovascular disease (CVD), or life-threatening illness\n* Known milk allergy\n* Has severe GI symptoms after drinking milk\n* History of GI surgery\n* Had a double mastectomy\n* Smoking\n* More than 1 alcoholic beverage\u002Fday\n* Pregnant or breastfeeding\n* Colonoscopy in last 2 weeks\n* Antibiotics in last 3 months\n* Taking probiotics or fiber supplements (if taking, must be able to stop taking during study)\n* Taking laxatives, stool softeners, anti-diarrheal (if taking, must be able to stop taking during study)\n* Taking lactase pills (if taking, must be able to stop taking)\n* Participating in extreme dieting program\n* Planning extended travel that would prevent participation in study\n* Taking medication that must be taken separate from calcium or dairy products","ALL","18 Years","70 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Individuals with lactase non-persistence (LNP; determined by a functional variant in the LCT gene \\[rs4988235, GG genotype\\]) are susceptible to lactose intolerance in adulthood due to deficiency of lactase, the enzyme which digests milk lactose sugars. However, many LNP individuals still drink ≥1 cup of milk daily. Recent analysis in the Hispanic Community Health Study\u002FStudy of Latinos (HCHS\u002FSOL) found that consumption of 1 serving (cup) of milk\u002Fday was associated with \\~30% lower risk of type 2 diabetes among LNP individuals, but not among individuals with lactase persistence (LP). This beneficial effect might be partially explained by favorable alterations in gut microbiota and related metabolites associated with higher milk consumption among LNP individuals. Based on these observational study findings, the investigator team proposes to conduct a randomized, controlled trial of lactose-containing vs. lactose-free milk in LNP individuals with pre-diabetes, to comprehensively investigate the effects of milk intake on the gut microbiome and glycemic outcomes.",[26,27,28,29,30],"Lactose Intolerance","Lactose Intolerant","Lactase Persistence","Pre-Diabetes","Diabetes Mellitus, Type 2",[32,33,34],"Lactose","Lactose-free","Lactase Non Persistence","RECRUITING","2026-05-21",{"date":38,"type":39},"2026-05-26","ACTUAL",{"date":41,"type":39},"2026-05-15",{"date":43,"type":20},"2028-04",{"name":45,"class":46},"Albert Einstein College of Medicine","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100587668","screening-of-lactose-intolerance-among-ibs-patients-diarrhea-dominant-100587668","NCT06931379","Screening of Lactose Intolerance Among IBS Patients Diarrhea Dominant","Screening for Lactose Intolerance Among Patients With IBS Diarrhea Dominant","Inclusion Criteria:\n\n* All Patients with IBS diarrhea dominant type meet Rome criteria attending at Al-Rajhy University Hospital during 6 months (from march to September). A patient must have recurrent abdominal pain (at least 1 day per week in the last 3 months) associated with at least two of the following:\n\n  1. Related to defecation (pain improves or worsens with bowel movements).\n  2. Change in stool frequency (diarrhea or constipation).\n  3. Change in stool form (appearance) (loose, watery, hard, or lumpy).\n* Patients aged \\>18 years.\n* Both males and females\n\nExclusion Criteria:\n\n* -patient aged\\\u003C18 years old.\n* Patients with chronic diarrhea don't meet Rome criteria\n* patients with malignancies",{"count":56,"type":20},70,"OBSERVATIONAL","This cross-sectional study aims to determine the prevalence of lactose intolerance among patients with chronic diarrhea, assess its correlation with age and gender, and evaluate common symptoms in affected patients. The study will collect demographic data, conduct lactose intolerance testing via PCR, and use a symptom questionnaire.",[26],[61,62],"lactose intolerance","chronic diarrhea","NOT_YET_RECRUITING","2026-01-04",{"date":66,"type":39},"2026-01-06",{"date":68,"type":20},"2026-01",{"date":70,"type":20},"2027-02",{"name":72,"class":46},"Assiut University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100529758","lactobreath-a-study-to-diagnose-lactose-intolerance-using-breath-markers-100529758","NCT06177938","Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath Markers","Lactobreath: A Pilot Study to Diagnose Lactose Intolerance Based on the Exhaled Breath Metabolome","Lactobreath","Inclusion criteria:\n\n* Men and women\n* Swiss and non-Swiss living in the Zurich area (if necessary, beyond Zürich in Switzerland),\n* Ability\u002Fdesire to provide informed consent and partake in the procedures of the study\n* Aged 18-65 years at screening\n* Agreement to refrain from all other treatments and products used for dairy intolerance (e.g., Lactaid® dietary supplements) during study involvement\n* Willing to return for all study visits and complete all study-related procedures, including fasting before and during the intervention\n* Able to understand and provide written informed consent in English and\u002For German.\n\nExclusion criteria:\n\n* Allergic to milk\n* Currently pregnant\n* Currently lactating\n* Cigarette smoking or other use of tobacco or nicotine-containing products within 3 months of screening\n* Diagnosed with any of the following disorders known to be associated with abnormal GI motility: gastroparesis, amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism\n* History of surgery that alters normal GI tract function, including but not limited to: GI bypass surgery, bariatric surgery, gastric banding, vagotomy, fundoplication, pyloroplasty (N.B. history of uncomplicated abdominal or GI surgeries such as removal of an appendix \\>12 months before screening will not be excluded)\n* Suspected obscure GI bleeding\n* Past or present: organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, coeliac disease, diverticular disease, inflammatory bowel disease, strictures (suspected or known), fistulas, or any GI obstruction, gastroparesis, history of gastric bezoar or any other medical condition with symptoms that could confound collection of adverse events\n* Diabetes mellitus\n* Congestive heart failure\n* Human immunodeficiency virus, hepatitis B, or hepatitis C\n* Body mass index \\> 35 kg\u002Fm2\n* Swallowing disorders or dysphagia to food or pills\n* Presence of implantable or portable electro-mechanical medical devices (e.g. pacemakers)\n* Recent bowel preparation for endoscopic or radiologic investigation within 4 weeks of screening (e.g., colonoscopy preparation)\n* Chronic antacid and\u002For proton pump inhibitor use\n* Recent use of systemic antibiotics, defined as use within 2 months prior to screening\n* History of ethanol (alcohol) and\u002For drug abuse in the past 12 months\n* Patients with severe irritable bowel syndrome (IBS) (i.e., IBS Symptom Severity Score \\>400)\n* Dietary restrictions including vegan or vegetarian diet.\n* Any other conditions\u002Fissues noted by the study staff and\u002For Principal Investigator that would impact participation and\u002For protocol compliance.\n* Previous enrollment in another clinical trial within the last 3 months.\n* Results of the screening test showing GI symptoms in response to lactose ingestion and genetic LP.",true,"65 Years",{"count":84,"type":20},120,[23],"Food intolerances affect many people and can cause discomfort and dietary challenges. One common cause is difficulty digesting certain carbohydrates called FODMAPs. Diagnosing food intolerance is often done by excluding and then slowly reintroducing these carbohydrates or using a hydrogen breath test, but these methods have limitations.\n\nTo address these issues, this project uses the breath we exhale to find markers for lactose intolerance as a model for food intolerance diagnosis. Our aim is to identify breath markers for lactose tolerance and intolerance and link them to metabolic traits, including those found in urine. We use a real-time breath analysis method and a special sensor to measure gases in the digestive system, and we also explore genetic factors using saliva samples.\n\nThis project aims to help clinicians better identify patients who should follow low FODMAP diets and provide non-invasive breath tests to predict how patients will respond to these diets. It will also advance the use of breath analysis for personalized nutrition, contributes to the broader field of food intolerance research, and has the potential to benefit millions of individuals worldwide.",[26],[32,89,90,91,92,93],"Food Biomarker","Metabolome","Food Intolerance","Microbiota","Breath","2025-07-02",{"date":96,"type":39},"2025-07-08",{"date":98,"type":39},"2024-06-24",{"date":100,"type":20},"2025-12",{"name":102,"class":46},"ETH Zurich",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":47},"100575543","proper-dietary-management-follow-up-and-lactase-enzyme-supplementation-for-lactose-intolerance-100575543","NCT06773650","Proper Dietary Management, Follow-up, and Lactase Enzyme Supplementation for Lactose Intolerance","Lactose Intolerance: a Guide to Proper Dietary Management, Follow-up, and Lactase Enzyme Supplementation","Inclusion Criteria:\n\n* Subjects must be adults (≥18 years of age)\n* Willingness to complete the online survey\n\nExclusion Criteria:\n\n* Subjects \\\u003C18 years of age\n* Subjects not available to answer the online survey",{"count":111,"type":20},385,"Lactose intolerance (LI) is considered the clinical syndrome caused by lactose malabsorption (LM).\n\nIt is possible to identify four causes of lactase deficiency defining four different types of LM: primary (genetic), secondary (acquired), congenital (alactasia), and developmental (in premature infants, so reversible).\n\nThe aim of this protocol is to investigate through an anonymous online survey the knowledge of the Italian population on clinical, pathophysiological, diagnostic and therapeutic issues of lactose intolerance. Data collected will be divulgated through a publication for both people with IL and nutritionists, enriched with tables and flow charts, to improve the knowledge on lactose intolerance and to support people suffering from this condition. The results of this survey will guide subjects suspected of suffering from lactose intolerance towards a correct diagnosis and a better management.",[27,114,26],"Lactose Malabsorption","2025-01-09",{"date":117,"type":39},"2025-01-14",{"date":119,"type":39},"2025-01-08",{"date":68,"type":20},{"name":122,"class":46},"European Institute of Oncology",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":47},"100446998","the-role-of-irritable-bowel-syndrome-in-lactose-intolerance-lion-100446998","NCT05100719","The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)","The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION Trial): Protocol of a Multicentre Randomized Controlled Clinical Trial","LION","Inclusion Criteria:\n\n* age 18-80 years\n* patients diagnosed with irritable bowel syndrome based on the ROME IV. criteria\n* positive LHBT (lactose H2 breath test) and LTT (lactose tolerance test) results\n* negative abdominal ultrasound\u002FCAT scan\u002FMRI results within one year\n* signed the informed consent\n\nExclusion Criteria:\n\n* organic gastroenterological disorders which can explain symptoms (e.g. positive serological screening: anti-gliadin IgG \u002F IgA, anti-tissue transglutaminase IgG \u002F IgA, high level of fecal calprotectin tested by endoscopy or positive colonoscopy for IBD, currently active diverticulitis\n* Alarm symptoms: fever (\\> 38 Co), anaemia (Hgb \\\u003C 120 g\u002Fl), unintended weight loss (\\> 4.5 kg \u002F 3 months), gastrointestinal bleeding (hematemesis, hematochesia, melena)\n* cardiac failure (NYHA III-IV)\n* liver cirrhosis (Child-Pugh C)\n* active malignancy\n* major abdominal surgery in the history\n* pregnant or breastfeeding women\n* any circumstances which can lead to false results of LHBT and LTT: cigarette smoking or physical exercise within 2 hours before the test, ingestion of dietary fibers on the evening before the test, recent use of antibiotics, lung disease, baseline H2 concentration in the exhaled air is higher than 20 ppm, not properly treated diabetes mellitus, following lactose restricted or another special diet within 1 week prior to study enrolment (ingestion of less than 12 g lactose - less than 250 ml milk - per day)\n* small intestinal bacterial overgrowth (SIBO): if there is a rapid increase of H2 level in the exhaled air (≥20 ppm above baseline within 90 minutes), SIBO is suspected and antibiotic therapy will be started (peroral rifaximin for 5 days) after negative Helicobacter pylori serology. After this procedure, lactulose H2 breath test will be performed to exclude SIBO (≥20 ppm H2 rise only after 90 min). In case of negative lactulose H2 breath test, another LHBT will be carried out\n* slow oro-cecal transit: clinical signs and typical findings on the tests (the LHBT is normal, but the increase of blood glucose level is less than 1.1 mmol\u002Fl and\u002For no H2 rise during lactulose H2 breath test)\n* milk allergy (positive IgE test)","80 Years",{"count":133,"type":20},200,[23],"Irritable bowel syndrome (IBS) is a functional gastrointestinal disease. There is no well-defined pharmacological treatment. This clinical trial is a prospective, double-blind, two-armed randomized controlled, single-center trial. It is created to examine the role of IBS in patients with lactose intolerance. IBS patients undergo lactose H2 breath test (LHBT) and lactose tolerance test (LTT). Those with positive LTT and LHBT will be randomized into two groups: alverine-citrate + simethicone and lactase group (1) or alverin-citrate + simethicone with the placebo group (2). The goal of this study is to compare the lactase enzyme with placebo in IBS patients with lactose intolerance.",[137,26,114],"Irritable Bowel Syndrome",[139,61,140,141,142,143,144],"irritable bowel syndrome","lactose malabsorption","lactase","simethicone","alverine-citrate","placebo","2021-10-19",{"date":147,"type":39},"2021-10-29",{"date":149,"type":20},"2022-09",{"date":151,"type":20},"2026-12",{"name":153,"class":46},"University of Pecs"]